HealthPharma & Biotech
Actinogen Medical Ltd

Actinogen Medical opens SPP after successful $15 million placement

Funding will go towards the company's lead drug candidate Xanamem™.

close up of connected cells in a brain
Alzheimer’s disease is the most common form of dementia

Actinogan Medical Ltd (ASX:ACW) will open a share purchase plan (SPP) to its shareholders at the same price as its recently completed $15 million share placement.

The recent placement included a $10.5 million cornerstone investment from leading US biotech investors Biotechnology Value Fund, L.P.

The SPP will be priced at 5 cents and be on a first-come, first-served basis capped at $2.0 million.

The offer opens today and will close 11 July 2018.


Advancing Alzheimer’s disease drug

Actinogen’s lead drug candidate Xanamem™ represents a novel approach to treating Alzheimer’s disease – a condition with a significant unmet medical need.

It blocks the production of stress hormone cortisol, which appears to contribute to cognitive impairment, amyloid plaques and neural death - hallmarks of Alzheimer’s disease.

Alzheimer’s growing rapidly

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and their loved ones.

Alzheimer’s is also growing rapidly and is now the second leading cause of death in Australia behind ischaemic heart disease.

The American Alzheimer’s Association estimates that the direct healthcare cost of the disease was $US250 billion in 2013, and by 2050, the cost of care for people with the disease is expected to be over $US1 trillion, outstripping the cost of treating all other diseases.

Proceeds to fund ongoing drug development

The proceeds from this SPP will support the ongoing development of Xanamem through the company’s development plan.

This plan includes, among others, a study exploring a higher dose of Xanamem in Alzheimer’s disease and studies conducted in alternative clinical indications.

Expansion of the development plan for Xanamem into these new indications will enhance the value of the company’s data set.

Quick facts: Actinogen Medical Ltd

Price: $0.01

Market: ASX
Market Cap: $8.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Blackstone Minerals PGE assays a game-changer at Vietnamese...

Blackstone Minerals Ltd (ASX:BSX) managing director Scott Williamson updates Proactive on its maiden drilling program at the Ta Khoa Nickel Project in northern Vietnam, which has delivered the project's first-ever PGE assays. Assay results from the first of three drill holes at Ta Khoa have...

1 hour, 47 minutes ago

2 min read